Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 8/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120470 | 0.76 | CHRM2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2HRH4 | |
| SCHEMBL13326560 | 0.73 | CYP1A2 (0.39) | KCNH2HRH4HRH3HRH2CYP1A2 | |
| SCHEMBL14477838 | 0.68 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2HRH4 | |
| SCHEMBL6896744 | 0.68 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2KDM1A | |
| SCHEMBL6896740 | 0.68 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2KDM1A | |
| SCHEMBL6895618 | 0.67 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3KCNH2HRH3 | |
| SCHEMBL12120471 | 0.67 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3KCNH2HRH3 | |
| SCHEMBL6895624 | 0.67 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3KCNH2HRH3 | |
| SCHEMBL239923 | 0.66 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2KDM1A | |
| SCHEMBL605459 | 0.66 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | PMV PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | SLC6A2 4587/4885SLC6A4 4151/4885SLC6A3 4397/4885 |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | SLC6A2 4532/4885SLC6A4 3952/4885SLC6A3 4117/4885 |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | SLC6A2 4587/4885SLC6A4 4151/4885SLC6A3 4397/4885 |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | SLC6A2 4454/4885SLC6A4 3754/4885SLC6A3 3961/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | SLC6A2 2519/4885SLC6A4 1630/4885SLC6A3 2591/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | SLC6A2 4836/4885SLC6A4 4547/4885SLC6A3 4562/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | SLC6A2 4587/4885SLC6A4 4151/4885SLC6A3 4397/4885 |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | TP53, TP53BP1, MDM2 | SLC6A2 4825/4885SLC6A4 4424/4885SLC6A3 4378/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | SLC6A2 4454/4885SLC6A4 3754/4885SLC6A3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.